Differences of the fecal microflora with clostridium difficile therapies

Clinical Infectious Diseases

Volumn 60, Issue , 2015, Pages S91-S97

  Louie, Thomas J ^a,b   Byrne, Brendan ^a   Emery, Judith ^a   Ward, Linda ^b   Krulicki, Wally ^b   Nguyen, David ^a   Wu, Kaiyu ^a   Cannon, Kristine ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

lactobacilli

Indexed keywords

CEFOXITIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; METRONIDAZOLE; TOLEVAMER; VANCOMYCIN; ANTIINFECTIVE AGENT; POLYMER; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG DOSE COMPARISON; FECES ANALYSIS; FECES CULTURE; FECES MICROFLORA; HUMAN; MAJOR CLINICAL STUDY; MICROBIOME; MINIMUM INHIBITORY CONCENTRATION; PATHOGEN CLEARANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; AGED; BACTERIAL LOAD; BACTEROIDETES; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; FECES; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; INTESTINE FLORA; ISOLATION AND PURIFICATION; LACTOBACILLUS; MALE; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; TIME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BACTEROIDETES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LACTOBACILLUS; MALE; METRONIDAZOLE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMERS; PROBIOTICS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84928883563     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ252     Document Type: Article

References (26)

1. Johnson S, Gerding DN, Louie TJ, Ruiz NM, Gorbach SL. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2012; 56: 4043-5.
2. Johnson S, Louie TJ, Gerding DN, et al. Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59: 345-54.
3. Cohen SH, Gerding DN, Johnson S, et al. Society for Health Care Epidemiology of America (SHEA), Infectious Diseases Society of America (IDSA). Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Health Care Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
4. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20(suppl 2): 1-26.
5. Stecher B, Maier L, HardtWD. "Blooming" in the gut: how dysbiosismight contribute to pathogen evolution. Nat Rev Microbiol 2013; 11: 277-84.
6. Sun X, Hirota SA. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. Mol Immunol 2015; 63: 193-202.
7. El Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr PI, Haslam DB. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 2013; 56: 1713-21.
8. Howerton A, Patra M, Abel-Santos E. A new strategy for the prevention of Clostridium difficile infection. J Infect Dis 2013; 207: 1498-504.
9. Semenyuk EG, Laning ML, Foley J, et al. Spore formation and toxin production in Clostridium difficile biofilms. PLoS One 2014; 9: e87757.
10. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; 5: CD006095.
11. Friedman G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am 2012; 41: 763-79.
12. Boonma P, Spinler JK, Venable SF, Versalovic J, Tumwasom S. Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol 2014; 14: 177.
13. Johnson S, Maziade P-J, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012; 16: e786-92.
14. Louie TJ, Peppe J, Watt CK, et al. Tolevamer Study Investigator Group. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 411-20.
15. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 223-8.
16. Louie TJ, Emery J, KrulickiW, Byrne B, MahM. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53: 261-3.
17. Hinkson PL, Dinardo C, Deciero D, Klinger JD, Barker RH Jr. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficle. Antimicrob Agents Chemother 2008; 52: 2190-5.
18. Louie TJ, Miller MA, Mullane KM, et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
19. Jousimies-Somer H, Summanen P, Citron DM, Baron EJ, Wexler HM, Finegold SM. Wadsworth-KTL anaerobic bacteriology manual. 6th ed. Belmont, CA: Star Publishing, 2002.
20. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI. Clin Infect Dis 2012; 55(suppl 2): S132-42.
21. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-98.
22. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-72.
23. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiologic response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 56-62.
24. Labbe AC, Poirier L, Maccannell D, et al. Clostridium difficile infections in a Canadian tertiary care hospital before and after a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 2008; 46: 1118-22.
25. Citron DM, Babakhani F, Goldstein EJ, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009; 15: 234-6.
26. Newton DF, Macfarlane S, Marfarlane GT. Effects of antibiotics on bacterial species composition and metabolic activities in chemostats containing defined populations of human gut microorganisms. Antimicrob Agents Chemother 2013; 57: 2016-25.